Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Change in Acquisitions & Divestments (2022 - 2024)

Gain Therapeutics (GANX) has 3 years of Change in Acquisitions & Divestments data on record, last reported at -$42502.0 in Q4 2024.

  • For Q4 2024, Change in Acquisitions & Divestments fell 101.35% year-over-year to -$42502.0; the TTM value through Dec 2024 reached $5.0 million, down 59.0%, while the annual FY2024 figure was $5.0 million, 59.0% down from the prior year.
  • Change in Acquisitions & Divestments reached -$42502.0 in Q4 2024 per GANX's latest filing, down from $2.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $4.1 million in Q1 2023 and bottomed at -$42502.0 in Q4 2024.
  • Average Change in Acquisitions & Divestments over 3 years is $2.4 million, with a median of $2.5 million recorded in 2022.
  • Peak YoY movement for Change in Acquisitions & Divestments: skyrocketed 51.45% in 2023, then crashed 101.35% in 2024.
  • A 3-year view of Change in Acquisitions & Divestments shows it stood at $2.1 million in 2022, then skyrocketed by 51.45% to $3.1 million in 2023, then plummeted by 101.35% to -$42502.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were -$42502.0 in Q4 2024, $2.0 million in Q2 2024, and $3.0 million in Q1 2024.